Australian-Canadian Prostate Cancer Research Alliance

2010 SYMPOSIUM

Welcome from the Director

On behalf of the Australian-Canadian Prostate Cancer Research Alliance I would like to welcome you to an exciting program for the 2010 Symposium.

This year, in the spirit of collaboration, we have asked experts from both countries to develop engaging, interactive and discussion based sessions around some key themes in prostate cancer research.

The Symposium hopes to bring together a wealth of knowledge, expertise, ideas and resources, in a format that engenders participation and stimulates exchange within the prostate cancer research communities across both continents; with the goal of advancing translational outcomes.

Your contribution is invaluable to building the strength of this exciting and growing network and I look forward to your continued involvement with the Australian-Canadian Prostate Cancer Research Alliance!

Best wishes,

Professor Colleen Nelson
Director
Australian-Canadian Prostate Cancer Research Alliance

The Aus-CanPCRA Directors
Prof Colleen Nelson
Prof Judith Clements
Dr Martin Gleave
Dr Robert Bristow

The Aus-CanPCRA Coordinators
Ally Tutkaluk – Australian Coordinator
Kathleen Barilla – Canadian Coordinator

2010 Symposium Full Program

Contents

Program at a glance

Time	Day 1: Friday August 6	Day 2: Saturday August 7	Day 3: Sunday August 8
9-10.30am	Arena 2 **Opening Plenary**	Arena 1B **Joint Plenary with the PCFA Scientific meeting**	Arena 1B **Joint Plenary with the PCFA Scientific meeting**
10.30-11am	Morning tea	Morning tea	Morning tea
11-12.30pm	Central Room A **Genomics of Prostate Cancer** Moderators: Dr Grant Buchanan and Prof Colleen Nelson	Central Room A **In Vivo Tumour Models** Moderators: Prof Pamela Russell and Dr YZ Wang	Central Room A **New aspects of prostate cancer endocrinology** Moderators: Dr Michael Pollak and Prof Wayne Tilley
12.30-1.30pm	Lunch	Lunch	Lunch
1.30-3pm	Central Room A **In Vivo Advanced Imaging: from pre-clinical to patient** Moderators: Dr Joe Chin and Prof Chris Langton	Central Room A **The Tumour Microenvironment** Moderators: Dr Rob Bristow and Dr Scott Williams	Central Room A **Wrap up – what next?** Prof Colleen Nelson
3-3.30pm	Afternoon tea	Afternoon tea	Afternoon tea
3.30-5pm	Central Room A **Preclinical to Clinical Advances** Panel of Clinicians	Central Room A **Biomarkers** Moderators: Dr John Mills and Dr Yves Fradet	Arena 2 **Closing Plenary**

Friday 6 August 2010

Session 1: Genomics of Prostate Cancer 11:00 – 12:30

From next gen-sequencing applications, ChIP-seq, Rip-ChIP, coding and non-coding RNA, genotyping, splicing, translocations to explore the prostate cancer genome - what we know and what we can learn.

Moderators

Dr Grant Buchanan
Research Fellow, Medicine, University of Adelaide

Prof Colleen Nelson
Executive Director, Australian Prostate Cancer Research Centre –Queensland
Professor & Chair, Prostate Cancer Research, Queensland University of Technology

Topics covered

This workshop will make use of the expertise and knowledge of a wide range of delegates to stimulate discussion around the following themes:

Data Generation

- Next Generation Technologies: Microarrays, non-coding RNAs, CGH, Sequencing – seq, ChIP-seq, Rip-chip, methylation, GWAS, and translocations.
- Capacity, expertise and collaborative opportunities
- Aus-CanPCRA members involved in global efforts; ICGC project, PRACTICAL consortium

Data Management

- Online data resources; analysis & bioinformatics; visualization and integration; and the importance of cross-platform comparisons

Friday 6 August 2010

Session 2: In Vivo Advanced Imaging: pre-clinical to patient 1:30 – 3:00

A look at prostate cancer through the myriad of 'lenses'- advanced imaging modalities available today and applications being developed for tomorrow.

Moderators

Prof Chris Langton
Professor of Medical Physics, Discipline of Physics, Queensland University of Technology

Dr Joe Chin
Professor, Urology & Oncology; Chair, Division of Surgical Oncology, University of Western Ontario

Topics covered

- In Vivo Perfusion Imaging of a prostate cancer with dynamic contrast enhanced CT
- Accurate Co-registration of multi-modality imaging for Correlation with Post-Operative Pathology
- Thoughts on IHC and Genetic Validation of MRI-based Prostate Imaging
- Hybrid Imaging-Augmented Diagnosis and Treatment
- Intra-fraction Robotic Ultrasound Guided Radiation Therapy
- Where to from here? What are the missing jigsaw pieces?

Participants leading discussion

Dr Joe Chin Division of Surgical Oncology, University of Western Ontario, Ontario, Canada

Dr Chris Langton Professor of Medical Physics, Discipline of Physics, Queensland University of Technology, QLD, Australia

Dr Ting-Yim Lee Director of PET/CT Imaging Research, Lawson Health Research Institute and Scientist, Robarts Research Institute, Ontario, Canada

Dr Rob Bristow Radiation Oncologist, Princess Margaret Hospital; Senior Scientist, Ontario Cancer Institute; Professor, University of Toronto, Ontario, Canada

Mr Chris Poole PhD Student, Medical Physics, Queensland University of Technology, QLD, Australia

Friday 6 August 2010

Session 3: Preclinical to Clinical Advances 3:30 – 5:00

A multidisciplinary clinical panel consisting of urologists, medical oncologists, radiation oncologists, imaging experts, endocrinologists, pathology, and allied health from both Australia and Canada will address some of the following themes:

- What is the most important clinical question that research should and could address?
- What are the measures needed to improve clinical care?
- How do we improve translational research opportunities and outcomes?
- How can we stimulate more clinical collaborations, through trials and research, between Australia and Canada?

Saturday 7 August 2010

Session 4: In Vivo Tumour Models 11:00 – 12:30

Current models for the study of prostate cancer, their applications, challenges and limitations and new models to fill the gaps. Models will range in use addressing cancer initiation, progression of cancer to castrate resistant disease, and studies of metastases including those to the bone.

Moderators

Prof Pamela Russell
Professor & Head, Biomedical Imaging & Prostate Cancer Models, APCRC-Q, Queensland University of Technology

Dr YZ Wang
Senior Scientist, Vancouver Prostate Centre & BC Cancer Agency

Topics covered

Participants will discuss current models, including xenografts, immunocompetent mice, knock-out models, and other transgenic mice & models. Workshop discussion will focus on key questions, such as; what applications will these models fit?; what are their limitations?; how can they be perfected?; are new models needed to fill the gaps? And can mechanisms be established to enable other researchers and scientists to share in this technology, and use of these models?

Participants leading discussion

Dr Yuzhuo Wang Senior Scientist, Vancouver Prostate Centre & BC Cancer Agency, BC, Canada

Prof Pamela Russell Professor & Head, Biomedical Imaging & Prostate Cancer Model, Australian Prostate Cancer Research Centre –Queensland, QUT, QLD, Australia

Dr Paul Rennie Director, Laboratory Research, Vancouver Prostate Centre; Professor, University of British Columbia, BC, Canada

Dr Carl Power Head, National Imaging Facility, Prince of Wales Clinical School, & Coordinator, Animal Imaging Lab, Faculty of Medicine, University of New South Wales, NSW, Australia

Dr Chris Ong Research Scientist, The Vancouver Prostate Centre & Assistant Professor, University of British Columbia, BC, Canada

Dr Patrick Humbert Group Leader, Research Division, Peter MacCallum Cancer Centre, VIC, Australia

Dr Ulla Simanainen Research Fellow, Medicine, Concord Clinical School, ANZAC Research Institute, NSW, Australia

Dr Luc Furic Postdoctoral Fellow, Biochemistry, McGill University, Quebec, Canada

Dr Lisa Butler Senior Research Fellow, University of Adelaide, SA, Australia

Saturday 7 August 2010

Session 5: The Tumour Microenvironment 1:30 – 3:00

Genetic instability, hypoxia and stromal-epithelial interactions: are these key features of prostate cancer which help to identify the aggressive cancers?

Moderators

Dr Rob Bristow
Radiation Oncologist,
Princess Margaret Hospital;
Senior Scientist, Ontario
Cancer Institute; Professor,
University of Toronto

Dr Scott Williams
Radiation Oncologist
Peter MacCallum Cancer Centre

Topics covered

- Key clinical questions for prostate cancer and the tumour microenvironment: Biomarkers and trials
- The biology of prostate hypoxia and approaches to targeting
- Biology of EMT and cancer aggression
- Are the kallikrein proteases major players in the tumour microenvironment in invasion and bone metastasis?
- Stromal-epithelial interactions and genetic stability-the story of telomeres
- The duality of intraprostatic estrogen effects
- The Way Forward?

Participants leading discussion

Dr Scott Williams Radiation Oncologist, Peter MacCallum Cancer Centre, VIC, Australia

Dr Rob Bristow Radiation Oncologist, Princess Margaret Hospital; Senor Scientist, Ontario Cancer Institute; Professor, University of Toronto, ON, Canada

Assoc Prof Rik Thomson Associate Professor and Principal Research Fellow, Director of Research, O'Brien Institute, VIC, Australia

Prof Judith Clements Professor & Head, Cancer Program, Institute of Health & biomedical Innovation, & Scientific Director, APCRC-Q, Queensland University of Technology, QLD, Australia

Dr Anthony Joshua Assistant Professor, University of Toronto & Clinician Scientist, University Health Network, ON, Canada

Dr Stuart Ellem Research Fellow, Centre for Urological Research, Monash University, VIC, Australia

Saturday 7 August 2010

Session 6: Biomarkers 3:30 – 5:00

Clinical needs, promises and limitations of new biomarker tests and research assays to improve our ability to assess the risk, better diagnose and predict the outcome of individual cases of prostate cancer.

Moderators

Prof John Mills
Director and Chair, Research Committee, National Board Prostate Cancer Foundation of Australia

Dr Yves Fradet
Professor and Chief, Department of Surgery/Urology
Laval University Quebec

Topics covered

- Gene-based prediction of progression for clinically localized prostate cancer patients following radical prostatectomy
- The role of ASAP1 in castration resistant prostate cancer
- Molecular pathways associated with ERG-rearranged, PTEN-deleted, castration-resistant prostate cancer
- Scribble deficiency: a novel model of prostate cancer
- Proteomics of prostate cancer: From discovery to validation of putative prognostic markers

Participants leading discussion

Prof John Mills Director and Chair, Research Committee, National Board, Prostate Cancer Foundation of Australia, VIC, Australia

Dr Yves Fradet Professor and Chief, Department of Surgery/Urology, Laval University Quebec, QC, Canada

Prof Rob Sutherland Director, Cancer Research Program, Garvan Institute, NSW, Australia

Dr Ladan Fazli Research Pathologist, Urologic Sciences, Vancouver Prostate Centre , BC, Canada

Dr Tarek Bismar Associate Professor, Pathology and Laboratory Medicine, Oncology, Biochemistry & Molecular Biology, University of Calgary, AB, Canada

Dr Helen Pearson Postdoctoral, Research (Cell Cycle and Cancer Genetics), Peter MacCallum Cancer Institute, VIC, Australia

Ms Yunee Kim PhD student, Institute of Medical Science, University of Toronto, ON, Canada

Sunday 8 August 2010

Session 7: New aspects of prostate cancer endocrinology 11:00 – 12:30

Prostate tumours within the endocrine milieu: the role of steroid and peptide hormones and the emerging importance of metabolic syndrome.

Moderators

Dr Michael Pollak
Professor & Alexander Goldfarb Research Chair in Cancer Research, McGill University, Montreal



Prof Wayne Tilley
Director & Dame Roma Mitchell Chair in Cancer Research, Dame Roma Mitchell Cancer Research Laboratories
Head, Centre for Cancer Research, Hanson Institute

Topics covered

- Contemporary approaches to hormonal therapy
- Dietary and metabolic factors, obesity, diabetes mellitus, and prostate cancer
- Insulin and prostate cancer: from population studies to laboratory models
- Rationale for metformin in prostate cancer treatment
- Targeting HSP90 to inhibit androgen receptor signalling and prostate cancer growth
- Strategies for knockdown and inhibition of the androgen receptor

Participants leading discussion

Dr Michael Pollak Professor & Alexander Goldfarb Research Chair in Cancer Research, Department of Oncology, McGill University, Montreal, QC, Canada

Prof Wayne Tilley Director & Dame Roma Mitchell Chair in Cancer Research, Dame Roma Mitchell Cancer Research Laboratories; Head, Centre for Cancer Research, Hanson Institute, SA, Australia

Dr Gary Wittert Mortlock Professor of Medicine, Head of the Discipline of Medicine, University of Adelaide; Senior Consultant Endocrinologist, Royal Adelaide Hospital, SA, Australia

Dr Anthony Joshua Assistant Professor, University of Toronto & Clinician Scientist, University Health Network, ON, Canada

Dr Margaret Centenera Postdoctoral Fellow, Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, SA, Australia

Dr Paul Rennie Director, Laboratory Research, Vancouver Prostate Centre; Professor, University of British Columbia, BC, Canada

Sunday 8 August 2010

Session 8: Wrap up 1:30 – 3:00

Summary of collaborative opportunities and how you can leverage from the Australian-Canadian Prostate Cancer Research Alliance

Prof Colleen Nelson
Executive Director, Australian Prostate Cancer Research Centre –Queensland
Professor & Chair, Prostate Cancer Research, Queensland University of Technology

How can you make use of the networks and opportunities provided by the Australian-Canadian Prostate Cancer Research Alliance? This session will give delegates some insights into how the Aus-CanPCRA can help facilitate new areas of prostate cancer research, training, exchanges, and international activities.

Participant Bios A-Z

Dr Stephen Assinder
Head, Andrology Research Group and Lecturer in Physiology, Physiology & Bosch Institute (Bosch Prostate Cancer Focus Group), University of Sydney
Dr Assinder's work is concerned with three main areas: the role of oxytocin in prostate disease; actin-binding proteins in regulation of the cytoskeleton, and their roles in prostate cancer; and the intergration of the AKT, PTEN and TGF-b pathways. This work is in collaboration with Profs Des Richardson and Qihan Dong, co-members of the Bosch Prostate Cancer Focus Group.

Dr Tarek Bismar
Associate Professor, Pathology and Laboratory Medicine, Oncology, Biochemistry & Molecular Biology, University of Calgary

Dr Bismar performed his medical studies in Syria, where he received his MD from Damascus University. He continued his postgraduate education at several US universities, including Washington University-St. Louis, Wayne State University in Michigan and Harvard University in Massachusetts. Dr Bismar specialized in pathology at Washington University in St. Louis. During his studies, he decided to continue his training in urological pathology and start his own prostate cancer research program. His research interests include; pathology; oncology; biomarkers; gene expression; proteomics; aCGH and FISH.

In addition to Dr Bismar's current role, he also supervises two post-doctorate candidates in the field of pathology. Dr Bismar has also received the PCF Young Investigator Award, and the Junior I Scientist Award from the Fonds de la Recherche en Santé du Québec. His work can be found in 38 publications and book chapters. He is also a reviewer for scientific journals such as Cancer Research, Clinical Cancer Research and Cancer.

Dr Rob Bristow
Radiation Oncologist, Princess Margaret Hospital; Senor Scientist, Ontario Cancer Institute; Professor, University of Toronto

Dr Bristow is currently a Clinician-Scientist and Professor within the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto. He is a Senior Scientist at the Ontario Cancer Institute and a Radiation Oncologist in Genitourinary cancers at the Princess Margaret Hospital (University Health Network).

His primary research interests are in DNA damage responses and repair, prostate cancer carcinogenesis and prediction of prostate cancer treatment response. He has active research programs and clinical trials pertaining to hypoxic cell targeting, use of synthetic lethality approaches to cancer treatment and combined molecular targeting with chemotherapy or radiotherapy.

He has past and current leadership roles as: Co-Director, STTARR Innovation Imaging Facility, MaRS/UHN; Head, Campbell Family Research Institute-PMH Prostate Cancer Research Program; Scientific Board Member, Ontario Cancer Biomarker Network; Chair, Translational Biology Advisory Group for Canadian Association of Radiation Oncology (CARO); Editor, 4th Edition Basic Science of Oncology; Twice a Canadian Foundation for Innovation (CFI) Awardee; Former Co-Administrator, Canadian Prostate Cancer BioResearch Network; Former Chair, Scientific and Medical Advisory Board and now VP, Strategic Partnerships and Networks, Prostate Cancer Canada; Lead, Canadian Prostate Cancer Genome Sequencing Project.

Participant Bios A-Z

He has been a member of NCIC and NIH Biomedical Awards Review Panels, the US Army Prostate Program Review Panel, PCRFC, PCF UK, CIHR, KWF-Dutch, CR-UK and MRC UK grants panels.

Dr Grant Buchanan
Research Fellow, Medicine, University of Adelaide

Dr Grant Buchanan's postdoctoral research was in high-throughput technology and bioinformatics applied to cancer, completed at the University of Adelaide and the University of Southern California.

His Molecular Ageing Laboratory Group initiated in 2009 at the University of Adelaide is applying these skills to a deeper understanding of steroid receptors in the cancer microenvironment. Specifically, Grant's group is looking at how the co-ordinated action of steroid hormones in different compartments of the breast and prostate (e.g. stromal and epithelial cells) control maintenance and homeostasis of these tissues, and how this control breaks down in cancer, ageing and under conditions of hormone intervention. Techniques applied include, next-generation sequencing, bioinformatics, high-throughput transcriptional assays , chromatin immunoprecipitation (ChIP), ChIP-sequencing, expression microarray analysis, siRNA knockdown, drug screening and novel animal models.

Dr Lisa Butler
Senior Research Fellow, The University of Adelaide

Dr Lisa Butler is a Senior research Fellow in the Dame Roma Mitchell Cancer Research Laboratories in Adelaide. She holds a Ph.D. in cancer biology from the University of Adelaide with postdoctoral training at Memorial Sloan-Kettering Cancer Centre in New York. During her time at MSKCC, Dr Butler was the first to demonstrate that a new class of histone deacetylase inhibitors, had potent biological activity against prostate tumours. This research initiated clinical trials for these agents in the USA, and since that time, the field of histone deacetylase inhibitors has expanded considerably, with major pharmaceutical companies now having development programs and over 10 agents in clinical trials. From 2002 she has worked in the Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) at the University of Adelaide and Hanson Institute. Dr Butler's initial research in the DRMCRL was supported by a postdoctoral research fellowship from the Prostate Cancer Foundation of Australia. Subsequently, Dr Butler was awarded a Florey Research Fellowship, and she currently holds a Senior Research Fellowship from Cancer Council SA. Dr Butler currently heads a molecular therapeutics research group in the DRMCRL, which focuses on novel combinatorial approaches (e.g. using histone deacetylases inhibitors, heat shock protein-90 inhibitors, and molecular agents such as dominant negative receptors), to target androgen signalling therapeutically in prostate and breast cancer. She also has a strong interest in the development and utilisation of preclinincal models of disease, including mouse models and human tissue explants.

Dr Maggie Centenera
Postdoctoral Fellow, Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide

Dr Centenera completed her honours degree in Physiology in 2003 and a PhD in prostate cancer research in 2008, both at the University of Adelaide. She is now undertaking her postdoctoral training at the Dame Roma Mitchell Cancer Research Laboratories within the University of

Participant Bios A-Z

Adelaide and Hanson Institute, with Professor Wayne Tilley and Dr Lisa Butler. Her research interests are in developing targeted treatments that can improve outcomes for men with prostate cancer. Dr Centenera recently developed an explant culture model of human prostate cancer and is using this unique resource to investigate novel approaches to target androgen receptor signalling.

Dr Joe Chin
Professor, Urology & Oncology; Chair, Division of Surgical Oncology, University of Western Ontario

Dr Chin graduated from the University of Toronto, Faculty of Medicine and completed his Urology training at the University of Western Ontario and Roswell Park Cancer Institute in New York State.

He had been Professor and Chair of the Division of Urology at the University of Western Ontario for 12 years and is now Chair of the Division of Surgical Oncology and Head of the Provincial Surgical Oncology Program for the Southwestern Ontario Region. Dr Chin is currently Chair of the Royal College of Physicians and Surgeons of Canada Specialty Committee in Urology, responsible for the Training and Evaluation of Canadian Urology Residents.

Dr Chin's laboratory and clinical research interests are in prostate cancer management, including minimally invasive and alternative forms of management. His clinical practice at London Health Sciences Centre is concentrated in Urologic Oncology. He has been a Canadian leader in such procedures as robotic assisted laparoscopic prostatectomy, cryosurgery and High Intensity Focused Ultrasound for prostate cancer.

Professor Judith Clements
Program Leader, Cancer Program, Institute of Health and Biomedical Innovation, Queensland University of Technology
Scientific Director, Australian Prostate Cancer Research Centre-Queensland

Prof Judith Clements is a nationally significant innovator and integrative leader in hormone dependent cancer research through her roles as Head of QUT's Cancer Program, Scientific Director of the new federally-funded Australian Prostate Cancer Research Centre-Queensland, and Principal Research Fellow of the National Health and Medical Research Council (NHMRC) of Australia.

Her personal research focuses on mechanistic and translational studies of the role of kallikrein (KLK) serine proteases in hormone dependent cancers, particularly PCa. She has been internationally "recognized for her pioneering research" into the molecular and cell biology of the KLKs by the award of the Silver (2000) and Gold (2007) international EK Frey-Werle Medals. Her work's impact on P Ca is illustrated by her key discovery in 2000 of an extended human KLK gene locus - from 3 known genes (including PSA) to 15 genes - which revolutionized the field as a source of potential new diagnostic and/or prognostic biomarkers and therapeutic targets for prostate cancer. This has been a focus of much of her work since. Other ground-breaking, recent discoveries include the roles of KLKs in the initiation and progression of prostate cancer (through epithelial to mesenchymal transition) and its propensity for bone metastasis. Her work with PRACTICAL is identifying new gene sequence variants (SNPs) which impact on the risk, diagnosis, prognosis and/or treatment of Prostate Cancer.

Nationally, she is the Chair of the virtual national prostate cancer tissue bank – the Australian Prostate Cancer BioResource and is a member of the Prostate Cancer Foundation of Australia's

Participant Bios A-Z

Queensland Board. She has served/does serve on a variety of research panels for the NHMRC as well as the NHMRC Academy and is currently an NHMRC nominee on the Queensland Institute of Medical Research Council, and a member of the Queensland Rhodes Scholar Selection Committee.

Dr Stuart Ellem
Research Fellow, Centre for Urological Research

Dr Stuart Ellem is a research fellow in the Prostate and Breast Cancer Research Group within the Department of Anatomy and Developmental Biology at Monash University, Australia. He received his Ph.D. for his work examining the role of aromatase in the prostate and in prostate cancer. His current research interests focus on the role of local estrogen signalling and metabolism in the prostate and prostate disease, and particularly the role that estrogen-induced inflammation plays in the development and progression of prostate cancer.

Dr Ladan Fazli
Research Pathologist, Urologic Sciences, Vancouver Prostate Centre

Currently Dr Fazli is in charge of directing the pathology lab in the Prostate Center at Vancouver General hospital, the biggest center for prostate cancer research in Canada, which she joined in 2002. From 1999 to 2002 she held the same position at Kinetek Pharmaceutical Inc, being a part of target discovery group.

Dr Fazli holds a medical degree and specialized in anatomical and clinical pathology from National University of Iran. She immigrated to Canada in 1996. Other than extensive experience as a pathologist in tumor and normal morphologic diagnosis, she has established and upgraded histopathology labs equipped with autostainer for IHC, CISH and FISH, Laser micro-dissection, Tissue micro-arrayer, digital image scanning and quantitative image analysis.

Dr Yves Fradet
Professor and Chief, Department of Surgery/Urology
Laval University Quebec

Dr Yves Fradet graduated from Laval University (Quebec, Canada) in 1981, and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center, with Drs Willet Whitmore and Lloyd Old. Since 1983, he has headed a research laboratory at the Laval University Cancer Research Centre at the University hospital, where he is also director of the urologic oncology section. He is a member of many national and international societies, including the American Association of Genitourinary Surgeons, and is often invited as a guest speaker at national and international meetings, as a visiting professor, and as a consultant to many organizations. He was the founding chairman of the Canadian Urologic Oncology Group from 1988 to 1995. He has been the chairman of the department of surgery at Laval University from 2000 to 2008. He has authored over 230 publications and book chapters, and 426 abstracts.

Dr Fradet's research activities involve translational laboratory research in tumour immunology; molecular biology of bladder and prostate cancer, and its applications to new diagnostics and treatments; epidemiological studies in bladder and prostate cancers; and clinical trials in prostate cancer, and other genitourinary cancers. Dr Fradet also has a very active practice in urologic oncology.

Participant Bios A-Z

Dr Luc Furic
Postdoctoral Fellow, Biochemistry, McGill University

Dr Furic obtained his PhD from University of Montreal for his work on RNA-protein interactions and mRNA stability. This project led to the discovery of a new mRNA decay mechanism termed Staufen-mediated decay (Kim, Furic, DesGroseillers and Maquat, Cell 2005). He then undertook his postdoctoral training in the laboratory of Dr Nahum Sonenberg at the Mcgill University Goodman Cancer Centre working on the role of regulating mRNA translation in prostate cancer.

Dr Furic is a Research Fellow of The Terry Fox Foundation through an award from the National Cancer Institute of Canada and he holds a postdoctoral training fellowship from the DOD US Army-Prostate Cancer Research Program. Dr Furic's research interests include: eIF4E; translation initiation; PI3K; MAPK; tumour invasion.

Dr Patrick Humbert
Group Leader, Research Division, Peter MacCallum Cancer Centre

Dr Patrick Humbert, BSc (Hons) University of Western Australia, PhD Walter and Eliza Hall Institute (University of Melbourne). In 1996, Dr Humbert undertook postdoctoral training at the Massachusetts Institute of Technology (MIT) where he made seminal contributions to understanding the mechanism of tumour proliferation. Since 2000, Dr Humbert has run an independent research laboratory at the Peter MacCallum Cancer Centre, Melbourne. His current focus is the study of how cell shape and orientation regulate stem cell function, organ formation and cancer. In particular, Dr Humbert's laboratory has made major inroads in understanding how the genetic program that controls cell orientation can prevent the development of tumours of the breast and prostate therefore opening novel ways to treat these diseases. In 2001, Dr Humbert was awarded a Special Fellowship from the Leukemia and Lymphoma Society of America. He is currently a recipient of a Biomedical Career Development Fellowship from the National Health and Medical Research Council of Australia.

Dr Anthony Joshua
Medical Oncologist, Princess Margaret Hospital, Ontario Cancer Institute

Dr Anthony Joshua completed his medical oncology training at the Royal Prince Alfred hospital in Sydney, Australia before moving to Toronto to complete a PhD under the supervision of Dr Jeremy Squire in prostatic carcinogenesis. He has since joined the Department of Medical Oncology at Princess Margaret Hospital, specialising in genito-urinary malignancy and melanoma. He is currently an Assistant Professor with the University of Toronto and a clinician-scientist at the University Health Network. His current research interests include the unfolded protein response (working with Dr Brad Wouters), autophagy in prostatic carcinogenesis, translational research in GU and melanoma trials and clinical trial design.

Miss Yunee Kim
PhD student, Institute of Medical Science, University of Toronto

Miss Kim is currently a first year PhD student at the University of Toronto, under the supervision of Drs Jeffrey A. Medin and Thomas Kislinger. Her current research focuses on the discovery of

prognostic biomarkers of prostate cancer, as well as the disambiguation of key molecular players that orchestrate the development and progression of prostate tumours.

Her undergraduate and Masters degrees focused on animal infections and immunity. Throughout her studies, she gained a tremendous amount of expertise and laboratory experiences by continuously being involved in helping graduate students with their research as an undergraduate summer student, and eventually conducting her own studies as a graduate student. Her Masters thesis involved the use of proteomics techniques to identify biomarkers for bacterial infections in dairy cattle. As a result of this, she became interested in proteomics and how it can be applied to numerous scenarios in order to answer various questions. Her background as a biologist combined with her experience in proteomics led her to pursue further studies in the field of cancer biology and cancer proteomics.

In September of 2009, she joined the Medin and Kislinger labs as a PhD student. The overall aims of her PhD thesis are to use proteomics to profile the proteomes of prostatic fluids from patients with aggressive and indolent tumours and to comparatively analyze them in order to: 1) identify prognostic markers of prostate cancer; and 2) to identify and elucidate the functional roles of proteins that mediate the progression of aggressive tumours and/or mitigate indolent tumours.

Prof Chris Langton
Professor of Medical Physics, Discipline of Physics, Queensland University of Technology

Professor Langton developed the technique of broadband ultrasonic attenuation (BUA) for the assessment of osteoporosis, and was awarded a DSc in 2007 for his extensive research contributions to science, technology and clinical translation. BUA was recognised in 2006 (EurekaUK) by Universities UK as one of the top "100 discoveries and developments in UK Universities that have changed the world" over the past 50 years.

He leads the Q-BIC (Quantitative Biomedical Imaging & Characterisation) research initiative. Current research projects include development of an ultrasound intra-fraction IGRTsystem, finite element analysis of X-ray images (FEXI), and quantification of bone marrow composition by magnetic resonance imaging. A rapidly developing theme is the 'Osteoporosis-Cancer Interface'. Of particular mention is the unique development of a radiation therapy immersive simulator for healthcare professional training and patient awareness.

He holds a number of Professional Fellowships including Institute of Physics, Institute of Physics & Engineering in Medicine (IPEM), American Institute for Medical and Biological Engineering, and Australasian College of Physical Scientists and Engineers in Medicine. He is also an Affiliate of the Royal College of Physicians. In February 2008, he was appointed Professor of Medical Physics at Queensland University of Technology in Brisbane. He also serves as Director of the Queensland Cancer Physics Collaborative, which has already secured over $2million of financial support.

Dr Ting-Yim Lee
Director of PET/CT Imaging Research, Lawson Health Research Institute and Scientist, Robarts Research Institute

Ting-Yim Lee, PhD is Director of PET/CT Imaging Research, Lawson Health Research Institute; a scientist with Robarts Research Institute; and a professor of Medical Imaging at the University of Western Ontario. He was recently awarded a CIHR Industry Partnered Chair in CT Functional and Molecular Imaging. He was trained in Nuclear Medicine Imaging and is experienced in tracer

kinetics modelling for the derivation of tissue functional and physiological parameters from data on tissue uptake of contrast agent or radiopharmaceuticals. To validate his modelling approaches, he has developed or used a variety of animal models including rodents, rabbits, dogs and pigs to study heart attack, stroke and cancer as well as undertaken patient studies when appropriate with different imaging modalities including CT, PET and MR. The methodology that he has developed for the measurement of brain, liver and tumour perfusion using dynamic contrast enhanced CT scanning has been licensed to GE Healthcare as the software CT Perfusion.

Dr John Mills
Director and Chair, Research Committee, National Board
Prostate Cancer Foundation of Australia

Prof Mills is a specialist physician, medical scientist and businessman. He holds a BS (Hons) from the University of Chicago and an MD (Hons, with specialization in microbiology) from Harvard Medical School. His clinical training, in infectious diseases and pulmonary medicine, was at Boston City Hospital and the University of California, San Francisco. He holds professorial appointments at UCSF, Monash University and RMIT. He previously held academic appointments at Howard University School of Medicine and the University of Melbourne.

Prof Mills has been actively involved in patient care since 1966 and conducting medical research since 1961. His research interests have been very broad, ranging from infectious diseases to altitude sickness and cancer, and are reflected in his publications.

Since 1992 Prof Mills has been increasingly involved in biomedical business. He was the Managing Director of the Burnet Institute, a not-for-profit Melbourne corporation engaged in medical research, from 1992 to 2002. He has held several Board positions and is presently an Executive Director of TissuPath P/L, Executive Chairman of Cavidi AB and a non-executive director of GBS Venture Partners and Phosphagenics.

Since 2006 he has been a director of the Prostate Cancer Foundation of Australia and Chair of its Research Committee. As a consequence of this position, and his involvement with a histopathology practice that has an extensive uropathology practice, he has become increasingly involved in prostate cancer research.

Participant Bios A-Z

Prof Colleen Nelson
Executive Director, Australian Prostate Cancer Research Centre –Queensland
Professor & Chair, Prostate Cancer Research, Queensland University of Technology

Professor Colleen Nelson is the founding Executive Director of the Australian Prostate Cancer Research Centre-Queensland and Chair of Prostate Cancer Research at Queensland University of Technology. Prof Nelson is also Director of the Australian-Canadian Prostate Cancer Research Alliance. Since arriving in Australia in 2007, Prof Nelson has been awarded >$13 million in research grants. Most recently she was awarded the prestigious Smart State Premier's Fellowship. Prior to her appointment in Australia, she was a founding scientist of The Prostate Centre in Vancouver.

Prof Nelson's expertise is in translational prostate cancer research, specifically in identification of potential therapeutic targets, their in vitro and in vivo validation, validation through molecular pathology approaches and their translation into potential clinical application. These outcomes are derived from her expertise in high throughput applications in gene (protein coding and non-coding) and tissue expression profiling, gene regulation, next gen sequencing applications, and bioinformatics , She is particularly interested in characterizing responses to androgen deprivation therapy and progression to castrate resistance and endocrine action of steroid hormones and insulin and insulin-related hormones. Prof Nelson has been on a number of Strategic and Scientific Advisory Boards for Biotech, NGOs and for Government. Prof Nelson was the inaugural Director of the Microarray Platform for Genome Canada 2000-2009.

Dr Christopher John Ong
Research Scientist, The Vancouver Prostate Centre
Assistant Professor, Department of Surgery and Department of Urologic Sciences, University of British Columbia

The primary focus of Dr Ong's research program is to understand the molecular mechanisms that govern the progression of prostate cancer from a state of androgen sensitivity to hormone independence with the hope of developing novel therapeutic strategies to prevent or delay the progression of prostate cancer to androgen independence. His primary focus has been on the PTEN tumour suppressor gene, which is among the most frequently mutated genes in cancer. One or both copies of PTEN is mutated in over 70% of primary prostate cancer and PTEN is completely inactivated in over 50% of advanced prostate cancer which correlates with a poor prognosis. Dr Ong's laboratory is currently studying how mutations of that gene confer protection of prostate cancer cells from cell death and resistance to chemotherapy as well as how loss of PTEN influences progression of prostate cancer cells to androgen independence. Implications from this research may lead to new therapeutic strategies designed to prevent or delay progression to androgen independence. Based on observations to date, Dr Ong is testing the potential utility of several classes of small molecule drugs that act to down-modulate the PI3K survival pathway in the treatment of prostate cancer. These novel compounds have tremendous promise as lead compounds for development of therapeutics that target a primary defect associated with prostate cancer and other malignancies. Dr Ong's laboratory is also involved in the development of unique prostate tumour model systems which are used to characterize the function of a number of genes in normal and malignant prostate biology.

In collaboration with Drs. Alice Mui, Gerald Krystal and Raymond Andersen, Dr Ong has also been involved in the discovery and development of a novel class of small molecule agonists of the SH2-containing inositol phosphatase, SHIP. From a high throughput SHIP enzyme screen of a natural product library consisting of organic extracts derived from marine invertebrates, Dr Ong and his

colleagues identified the meroterpinoid Pelorol from the Papua New Guinea sponge, Dactylospongia elegans, as a novel small molecule agonist of SHIP. Subsequently, synthetic structural analogs of the natural product possessing more potent biological activity were identified, namely AQX-016A and AQX-MN100. They have now devised an efficient, high yielding chemical synthetic protocol for production of this new family of compounds. Furthermore, they have performed extensive studies in wild-type and SHIP-deficient cells and in animal models of inflammation and cancer to demonstrate oral bioavailability, specificity, and efficacy of these compounds as a robust activator of SHIP and as a potent anti-inflammatory and anti-leukemia/lymphoma agent.

Dr Ong is a scientific founder of Aquinox Pharmaceuticals Inc., a biopharmaceutical company focused on development of targeted small molecule therapeutics for treatment of cancer and inflammation. Aquinox was formed as a spin-off company from UBC, The Prostate Centre and BCCRC as a vehicle to facilitate the commercialization of SHIP agonists for treatment of inflammatory diseases and cancer. In June 2007, Aquinox raised US$14.5 million in a Series A venture capital financing from a strong cross-border syndicate led by Ventures West Capital Ltd. and included Johnson and Johnson Development Corp., Baker Brothers Investments and BC Advantage Funds, managed by Lion's Capital Corp. This financing will allow Aquinox to advance its lead compound through pre-clinical studies to commence a Phase I clinical trial in patients with certain forms of blood cancers in early 2009.

Dr Helen Pearson
Postdoctoral Research Fellow (Cell Cycle and Cancer Genetics), Peter MacCallum Cancer Institute

Throughout Dr Pearson's degree in Biochemistry she developed an interest in cell signalling and the molecular genetics of cancer biology. To this end, she undertook a summer studentship assisting a breast cancer clinical trial which led her to the field of cancer research. Subsequently, she secured a PhD position at Cardiff University with Prof Alan Clarke where she developed and characterised novel models of prostate cancer. During this research Dr Pearson became fascinated with the molecular mechanisms that predispose prostate cancer, which led to her current postdoctoral position with Dr Patrick Humbert, investigating the role of the polarity regulators and prostate cancer.

Dr Michael Pollak
Professor, McGill University, Montreal

Dr Michael Pollak holds the Alexander Goldfarb Research Chair in Cancer Research at McGill University, Montreal, Canada, and directs the Division of Cancer Prevention of the Department of Oncology. He practices medical oncology at the Jewish General Hospital in Montreal, and is involved in clinical trials of novel agents related to growth factor targets. He also runs a research lab at the Lady Davis Research Institute, which is affiliated with the Hospital and McGill. The laboratory conducts research focusing on insulin and IGF physiology in relation to cancer, and also provides specialized ELISA assays for epidemiologic and pharmaceutical collaborators.

Dr Pollak has published more than 200 research papers and collaborates with leading cancer research groups worldwide in laboratory, clinical, and epidemiologic studies related to the role of growth factors in human cancer.

Participant Bios A-Z

Mr Christopher Poole
PhD Student, Medical Physics, Queensland University of Technology

Christopher is currently pursuing a PhD in Medical Physics under the supervision of Prof. Christian Langton and Dr Jamie Trapp at Queensland University of Technology, Australia. His primary research topic focuses on robotic ultrasound image-guided radiotherapy; specifically the proof-of-concept and scientific validation of this technology. More generally, his research interests are in the fields of adaptive and real-time image segmentation and Monte Carlo modelling for radiation transport.

Dr Carl Power
National Imaging Facility Fellow, Prince of Wales Clinical School
Coordinator, Animal Imaging Lab, Faculty of Medicine, University of New South Wales

Dr Carl Power is a National Imaging Facility Fellow in the Prince of Wales Clinical School, and coordinator of the Animal Imaging Lab in the Faculty of Medicine, University of New South Wales. Dr Power heads a small research program in prostate cancer bone-metastasis, and tumour immunity/immunotherapy Syngeneic mouse models are essential to this work. Two sygeneic models of prostate cancer bone-metastasis have been created in the lab, the RM1(BM) and the TRAMP-M models, both of which metastasise with high frequency to bone when injected into mice by intra-arterial routes. Both models also show a mixed osteosclerotic/osteolytic phenotype in bone like clinical prostate cancer bone metastasis. These models are used for diverse research applications including identification of the mechanisms for bone metastasis; study of the interactions between bone tissue, tumours and the immune system; and evaluation of potential therapies for treatment and prevention of bone cancers.

Dr Paul S. Rennie, PhD, FCAHS
Director, Laboratory Research, The Vancouver Prostate Centre
Professor, Department of Urologic Sciences and Department of Pathology and Laboratory Medicine, UBC

Dr Rennie is the co-founder and Director of Laboratory Research for the Prostate Centre at Vancouver General Hospital. His lab has had a long history of characterizing hormone regulation of prostate cancers and has contributed much of the groundwork for development of widely used, cost-efficient treatments for advanced prostate cancer in the 80's and for providing the mechanistic basis for intermittent androgen suppression treatment protocols. For example, they compared the relative effectiveness of different combinations of androgen withdrawal therapies in an animal model and based on this, developed a very cost-efficient and widely used treatment for advanced prostate cancer. Similarly, his lab's early work on the differentiation effects of low doses of androgens led to the first studies of intermittent androgen suppression in animal models, which continues to be used in a variety of clinical trial scenarios. His group was also amongst the first to show clusterin expression in androgen-dependent tumours, its potential role in tumour progression, and its function as a cell survival gene. Recently, several Phase I/II and III trials testing the efficacy of antisense oligonucleotides targeting clusterin (OGX-011) have been shown to enhance anti-androgen and chemosensitivity of prostate cancers.

Dr Rennie's current research is aimed at determining how androgens regulate gene transcription and how to use this knowledge to prevent progression to androgen independence in prostate cancers. A considerable amount of this research is directed towards identifying the molecular

elements that define androgen receptor and tissue specificity as well as designing siRNA delivery systems for knocking down the androgen receptor in tumours. Development of small molecule inhibitors of the androgen receptor is another major area of his research interests. In addition, he is working to develop oncolytic vesicular stomatitis and herpes viruses that can selectively infect and kill prostate tumour cells through cell lysis while sparing normal tissues.

As Director of Laboratory Research for the Prostate Centre, and as PI of the Terry Fox/NCIC Program Grant on Prostate Cancer Progression, Dr Rennie has established an integrated, multidisciplinary group to study molecular, cellular and translational aspects of prostate cancer progression to androgen independence. The program grant, which was initially awarded in 1998, is ongoing and has been repeatedly renewed, yielding over $15million in research funds. This program has provided the central thematic basis for much of the research currently performed at the Prostate Centre and established core facilities which were the nucleus of gene array, pathology and animal model activities.

In recognition of his achievements in science, Dr Rennie was named a Fellow of the Canadian Academy of Health Sciences in 2007.

Prof Pamela Russell
Professor, Australian Prostate Cancer Research Centre – Queensland, Queensland University of Technology

Prof Pamela Russell trained in immunology at Walter & Eliza Hall Institute. In 1984, she joined Dr Derek Raghavan to establish the Urological Cancer Research Centre at Royal Prince Alfred Hospital/University of Sydney and became director of the Oncology Research Centre (ORC), Prince of Wales Hospital from 1992, holding a conjoint chair in Medicine, UNSW. In 2009, she joined the Australian Prostate Cancer Research Centre – Queensland.

Her laboratory has an international reputation for its work on genitourinary cancer, and has established cell lines and rare xenografts from primary human bladder and prostate tumours. Most recently, her team has established new animal models for studies of bony metastases from prostate cancer, including those grown in immunocompetent mice, where interactions of growth factors common to bone cells and immune cells can be investigated.

Recent highlights by her team include production of a monoclonal antibody which binds 70% of prostate cancers, currently undergoing assessment for potential development as a diagnostic reagent and for targeted nanoparticle imaging; development of a first-in-man gene therapy for late stage prostate cancer, which is pending a Phase I clinical trial.

Prof Russell helped to establish the Animal Imaging Facility at The University of New South Wales for preclinical studies, and is now involved in the development of a preclinical imaging facility at the Australian Prostate Cancer Research Centre – Queensland to be part of the new Translational Research Institute, within the Princess Alexandra Biomedical precinct.

Prof Russell has received numerous prestigious awards over her career including the Medal of Australia for contributions to bladder and prostate cancer research; Life Memberships in PCFA (2006) and the Australasian Gene Therapy Society Award (2009).

Participant Bios A-Z

Dr Ulla Simanainen
Research Scientist, ANZAC Research Institute

Dr Simanainen is an early career scientist awarded her PhD from University of Kuopio, Finland, in June 2004. Her research career started in toxicology with her PhD thesis being primarily toxicology and pathology of dioxins with specific focus on male reproductive (including prostate) effects. Dr Simanainen was successful in obtaining her own funding - Endeavour Research Fellowship (Australian Government) and Academy of Finland Post-Doctoral Fellowship and to do her post-doctoral studies at the ANZAC Research Institute (Andrology lab, with Prof DJ Handelsman) in Sydney. End of 2006, Dr Simanainen won a NSW Cancer Institute Early Career Fellowship to continue her work on experimental prostate cancer models. Her work at ANZAC Research Institute has focused on androgen (and glucocorticoid) action highlighting cell-specific androgen role in prostate development, functional maturation and pathology using genetic mouse models.

Prof Rob Sutherland
Director, Cancer Research Program, Garvan Institute

Professor Rob Sutherland, Director of Garvan's Cancer Research Program, has been awarded an Officer of the Order of Australia (AO) "for distinguished service to medicine as an international contributor to the research of cancer, the development of Australia's research capacity and through leadership roles in advisory bodies". Announced in The Queen's Birthday 2010 Honours List, he was one of 21 people to receive the AO.

Over the past 25 years, Professor Sutherland has established one of Australia's largest cancer research programs, predominantly in the fields of breast and prostate cancer. Output from the program has included over 300 peer-reviewed publications in scientific journals, as well as several patents covering new methods of detecting cancer and new treatment strategies.

In 2002, Professor Sutherland was admitted as a Fellow of the Australian Academy of Science; in 2003 he was awarded the Centenary of Federation Medal for his service to Australian society and science in molecular and cellular biology; in 2009 he was awarded Life Membership of the Australian Cancer Research Foundation; and last month he was awarded the NSW Premier's Award for Outstanding Cancer Researcher 2010.

Professor Sutherland has served on various committees of the National Health and Medical Research Council (NHMRC), the Cancer Council NSW, the Cancer Institute NSW and Cancer Australia. He is also a former Board member of the Cancer Council NSW and the Cancer Institute NSW.

He has been appointed Director of The Kinghorn Cancer Centre, a translational cancer research centre, currently under construction, where clinical challenges will drive laboratory research. The joint initiative with St. Vincent's Hospital, expected to open in late 2011, will focus on the realisation of personalised medicine for cancer patients.

Associate Professor Erik Thompson
Associate Professor and Principal Research Fellow; Director of Research, O'Brien Institute; Research Higher Degrees Co-ordinator

Research interests include extracellular matrix, particularly basement membrane, in cancer invasion and metastasis and also tissue engineering. Matrix metalloproteinases as targets in breast

cancer progression, the process of epithelial-mesenchymal transition in cancer progression. Key molecular interests in MMPs, ECM proteins, SPARC, Galectin-3, integrins, cell adhesion, migration, invasion. Rik is the Director of Research for the O'Brien Institute. He is also the Research Higher Degrees Co-ordinator for the Department of Surgery, St Vincent's Hospital.

Prof Wayne Tilley
Director & Dame Roma Mitchell Chair in Cancer Research, Dame Roma Mitchell Cancer Research Laboratories
Head, Centre for Cancer Research, Hanson Institute

Professor Tilley is Director of the Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide and Hanson Institute, which incorporates more than 50 researchers and clinicians working on breast and prostate cancer. Professor Tilley returned to Australia in late 1990 after a NHMRC CJ Martin Fellowship at UT Southwestern in Dallas, Texas where he was one of the first to clone the human androgen receptor (AR). In 1997 he was appointed Director of the Flinders Cancer Centre. Following a sabbatical in the Department of Preventive Medicine, the Norris Cancer Center, University of Southern California in 2002, Prof Tilley relocated to the University of Adelaide/Hanson Institute to take up the position of the Dame Roma Mitchell Chair in Cancer Research. Since that time he has developed a research program on hormone action in breast and prostate cancer, and played an integral role in the development of the Adelaide Prostate Cancer Cancer Research Centre and the Freemasons Foundation Centre for Men's Health.

Prof Tilley's laboratory has made a major contribution to understanding the molecular mechanisms of resistance to hormonal therapies used in the treatment of prostate cancer. In particular, his laboratory has shown that continued signalling via the AR is an important determinant of disease progression and treatment response in all stages of prostate cancer. A current major research focus is the development of new treatments for prostate cancer that target the AR. Prof Tilley's laboratory has also pioneered research into understanding the pivotal role of AR in counteracting the proliferative effects of estrogens in the breast.

Dr YZ Wang
Senior Scientist, Vancouver Prostate Centre, BC Cancer Agency

Dr YZ Wang has a dual appointment as a Senior Scientist at the Vancouver Prostate Centre and the BC Cancer Agency. He is also an Associate Professor at the University of British Columbia (UBC).

In addition to proposing novel hypotheses on "prostate stem cells" and "epithelial-immune cell transition (EIT)", Dr Wang is also responsible for the development of a novel method for establishing patient-derived cancer tissue xenograft models in SCID mice with a high engraftment rate. So far, his living tumour laboratory (www.livingtumorlab.com) has developed over 150 transplantable tumour tissue lines that closely resemble patients' malignancies in terms of histopathology, genetic profiles and drug sensitivities. His current research continues focusing on applications of such xenograft models for: discovery and validation of potential biomarkers and/or therapeutic targets; preclinical drug efficacy studies in anti-cancer therapeutics development; and personalized cancer therapy.

Dr Wang has received numerous awards for his academic achievements in cancer research, such as the Prostate Cancer Foundation Research Award (2006), the Translation Research Award from Roche (2009), the Overseas Chinese Scholars Award (Distinguished Young Scholar Award,

Participant Bios A-Z

Category B) from the National Natural Science Foundation of China (2009), and the Innovative Scholar Award from the International Cancer Alliance for Research and Education (ICARE) (2010).

Dr Scott Williams
Radiation Oncologist, Peter MacCallum Cancer Centre

Scott Williams is a native of Queensland, where he trained in radiation oncology. He is now a consultant Radiation Oncologist with the Peter MacCallum Cancer Centre Uro-Oncology service in Melbourne where he has a special interest practice almost exclusively of locally advanced or recurrent prostate cancer following surgery . His long-term research interests are in prostate cancer radiobiology, PSA dynamics and analysis of cancer outcomes. Scott is involved in managing several national and international randomised trials in prostate cancer, and the lead investigator of another randomised study under development. He chairs the prostate subcommittee of the national ANZUP trials group, and sits on several national research and advisory committees. He presently holds an American Prostate Cancer Foundation Creativity Award for a novel translational research project, as well as being a collaborator on active research grants totalling more than $3.5M for studies ranging from clinical trials to functional imaging to mathematical modelling.

Dr Gary Wittert
Mortlock Professor of Medicine, Head of the Discipline of Medicine, University of Adelaide
Senior Consultant Endocrinologist, Royal Adelaide Hospital

Gary Wittert, a graduate of the University of Witwatersrand, Johannesburg, South Africa, is Mortlock Professor of Medicine and Head of the Discipline of Medicine, University of Adelaide, and Senior Consultant Endocrinologist Royal Adelaide Hospital. He is a Chief Investigator in the NH&MRC Centre of Clinical Research Excellence for Nutritional Physiology, Founding member of the Freemasons Foundation Centre for Men's Health Research, and initiated and oversees the Florey Adelaide Male Ageing Study, which is currently funded by the NH&MRC. Professor Wittert is the Independent Chair of the Weight Management Council of Australia and Vice President of the Asia Oceania Society for the Study of Obesity.

His research is undertaken at basic, clinical and population health levels. In the area of men's health he has a particular interest in androgen physiology, and the relationship between androgens, obesity and the metabolic syndrome. He has authored ~150 peer reviewed journal articles and book chapters. He has had on-going funding from the NH&MRC and /or ARC since 1994.

Attendee Contacts

Mr Mark Adams
PhD Student
Australian Prostate Cancer Research Centre-Qld, QUT
mn.adams@qut.edu.au
Australia

Dr Manuel Altamirano-Dimas
Emeritus Clinical Assis. Prof
University of British Columbia
manuel@interchange.ubc.ca
Canada

Miss Laura Amorim
PhD candidate
Australian Prostate Cancer Research Centre-Qld, QUT
laura.amorim@qut.edu.au
Australia

Dr Jiyuan An
postdoc
Australian Prostate Cancer Research Centre Qld, QUT
j.an@qut.edu.au
Australia

Dr Stephen Assinder
Lecturer
University of Sydney
stephena@physiol.usyd.edu.au
Australia

A/Prof Vicky Avery
Chief Investigator
Griffith University
v.avery@griffith.edu.au
Australia

Dr Preetika Balanathan
Research Fellow
Monash University
preetika.balanathan@med.monash.edu.au
Australia

Mr Stuart Baptist
Senior Physiotherapist
Mens Health Physiotherapy
stuartbaptist@ssop.com.au
Australia

Dr Jyotsna Batra
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
jyotsna.batra@qut.edu.au
Australia

Ms Annette Bezear
Physiotherapist
napier.girl@hotmail.com
Australia

Dr Tarek Bismar
Associate Professor
University of Calgary
tabismar@ucalgary.ca
Canada

Ms Kate Bolam
PhD Student
The University of Queensland
k.bolam@uq.edu.au
Australia

Dr Rob Bristow
Professor & Radiation Oncologist
University Health Network/STARR
Rob.Bristow@rmp.uhn.on.ca
Canada

Mr Ben Brooks
University of Queensland
ben.brooks@cmr.uq.edu.au
Australia

Dr Grant Buchanan
Research Fellow, Head Molecular Ageing Laboratory
University of Adelaide
grant.buchanan@adelaide.edu.au
Australia

Dr Pascal Buenzli
The University of Western Australia
pascal.buenzli@uwa.edu.au
Australia

Dr Lisa Butler
University of Adelaide
lisa.butler@health.sa.gov.au
Australia

Dr David Camp
Director - Queensland Compound Library
Griffith University
david.camp@griffith.edu.au
Australia

Ms Lyndy Carolan
Nurse
St Vincnets Private Hosptial
kashton@stvincents.com.au
Australia

Dr Maggie Centenera
University of Adelaide
margaret.centenera@adelaide.edu.au
Australia

Mr Daryl Cheng
Medical Student
Monash Univeristy
daryl_cheng@hotmail.com
Australia

Attendee Contacts

Dr Artem Cherkasov
Assistant Professor
University of British Columbia
acherkasov@prostatecentre.com
Canada

Ms Lyn Cherry
Supportive Care Development Officer
Bendigo Health - LMICS
lcherry@bendigohealth.org.au
Australia

Dr Joe Chin
Professor, Urology & Oncology;
Chair, Division of Surgical Oncology
University of Western Ontario
joseph.chin@lhsc.on.ca
Canada

Prof Judith Clements
Professor, Head, Cancer Program, IHBI & Scientific Director
Australian Prostate Cancer Research Centre-Qld, QUT
j.clements@qut.edu.au
Australia

Mrs Jeanette Collett
Registered Nurse
Nambour Selangor Private Hospital
colletts@iprimus.com.au
Australia

Ms Sanja Coso
Monash University
Sanja.Coso@monash.edu
Australia

Dr Geoff Coughlin
Staff Specialist
Royal Brisbane Hospital
drgcoughlin@me.com
Australia

Mrs Jennifer Crisp
Practice Nurse
Brisbane Urology Clinic
nurse@brisbaneurologyclinic.com.au
Australia

Mrs Carolyn Crowle
Clinical Nurse
Sir Charles Gairdner Hospital
Carolyn.Crowle@health.wa.gov.au
Australia

Mr Jonas Cruz
Physiotherapist
Blue Care
j.cruz@bluecare.org.au
Australia

Dr James Davie
Professor
University of Manitoba
davie@cc.umanitoba.ca
Canada

A/Prof Ian Davis
Ludwig Institute for Cancer Research / Austin Health / ANZUP
ian.davis@ludwig.edu.au
Australia

Dr Antonio de Sousa
Monash University
tony_desousajr@hotmail.com
Australia

Dr Katie Dixon
Postdoctoral Fellow
University of Sydney
katie.dixon@sydney.edu.au
Australia

Dr Jason Dowling
Research Scientist
CSIRO AEHRC
jason.dowling@csiro.au
Australia

Mrs Fran DuRietz
Registered Nurse
Selangor Private Hospital
glenandfran@dodo.com.au
Australia

Dr Michael Eisbacher
Medical Advisor - Oncology
Janssen-Cilag
meisbac1@its.jnj.com
Australia

Ms Jennifer Ellacott
Queensland University of Technology
jenM@qimr.edu.au
Australia

Dr Stuart Ellem
Research Fellow
Monash University
stuart.ellem@monash.edu
Australia

Miss Grace Eng
Queensland University of Technology
g.eng@qut.edu.au
Australia

Dr Ladan Fazli
Research Pathologist
Vancouver Prostate Centre
ladan.fazli@vch.ca
Canada

Attendee Contacts

Mr Rocco Fazzolari
CFO
Prostate Cancer Canada
rocco.fazzolari@prostatecancer.ca
Canada

Ms Alison Ferguson
Garvan Institute of Medical Research
aferg_01@hotmail.com
Australia

Ms Karen Fittall
Journalist
Atlantis Healthcare
sophelia.myers@atlantishealthcare.com
Australia

Dr Yves Fradet
Professor & Chief, Department of Surgery/Urology
University of Laval
Yves.Fradet@crhdq.ulaval.ca
Canada

Miss Ruth Fuhrman-Luck
PhD research student
Queensland University of Technology
r.fuhrmanluck@qut.edu.au
Australia

Dr Maggie Fung
Clinical Coordinator
Australian Prostate Cancer Research Centre-Qld, QUT
maggie.fung@qut.edu.au
Australia

Dr Luc Furic
Postdoctoral Fellow
McGill University
luc.furic@mcgill.ca
Canada

Associate Prof Daniel Galvao
Director
Edith Cowan University
d.galvao@ecu.edu.au
Australia

Ms Soula Ganiatsas
CEO
Victorian Prostate Cancer Research Consortium
soula.ganiatsas@vpcrc.org.au
Australia

Dr Jenni Gunter
Research Fellow
Australian Prostate Cancer Research Centre-Qld, QUT
jennifer.gunter@qut.edu.au
Australia

Dr Rohan Hall
Urology Registrar
Royal Brisbane and Women's Hospital
rohanhall@ausdoctors.net
Australia

Ms Patricia Halliday
CNC
Qld Health HACC Services
trish_halliday@health.qld.gov.au
Australia

Dr Janelle Hancock
Research Officer
UQ Centre for Clinical Research
j.hancock3@uq.edu.au
Australia

Dr Jonathan Harris
Senior Lecturer
Institute of Health and Biomedical Innovation
j2.harris@qut.edu.au
Australia

Dr Anne-Maree Haynes
Garvan Institute of Medical Research
a.haynes@garvan.org.au
Australia

Dr Nicole Haynes
Postdoctoral scientist
Peter MacCallum Cancer Centre
nicole.haynes@petermac.org
Australia

Dr Peter Heathcote
Doctor
Princess Alexandra Hospital
heathcote@brisbaneurologyclinic.com.au
Australia

Dr Luke Henderson
Lecturer
Deakin University
luke.henderson@deakin.edu.au
Australia

Dr Parisa Hesami
PhD student
Queensland University of Technology
p.hesami@qut.edu.au
Australia

Dr Geoff Hicks
Professor
University of Manitoba
hicksgg@cc.umanitoba.ca
Canada

Dr Michelle Hill
University of Queensland
m.hill2@uq.edu.au
Australia

Attendee Contacts

Dr Jeff Holst
Associate Faculty
Centenary Institute
jeffh@centenary.org.au
Australia

Dr Matthew Hong
Urology Research Fellow
University of Melbourne
mkhhong@gmail.com
Australia

Dr John Hooper
Senior Research Fellow
Australian Prostate Cancer Research Centre-Qld
jd.hooper@qut.edu.au
Australia

Assoc.Prof David Horsfall
Project Manager
Australian Prostate Cancer BioResource
david.horsfall@adelaide.edu.au
Australia

Dr Christopher Hovens
Melbourne University
cbhovens@gmail.com
Australia

Dr Patrick Humbert
Group Leader
The Peter MacCallum Cancer Centre
patrick.humbert@petermac.org
Australia

Dr Tzong-Tyng Hung
Postdoctoral research fellow
University of New South Wales
t.hung@unsw.edu.au
Australia

Ms Shirin Hussain
PhD Student
Monash University
shus3@student.monash.edu.au
Australia

Prof Dietmar W. Hutmacher
Chair of Regenerative Medicine
Queensland University of Technology
dietmar.hutmacher@qut.edu.au
Australia

Dr Kerry Inder
Research Officer
Diamantina Institute for Cancer, Immunology and Metabolic Medicine
k.inder@uq.edu.au
Australia

Dr Takamitsu Inoue
Department of Oncology, McGill University
takmitz@gmail.com
Canada

Mrs Susan Johnson
Lab Technician
Australian Prostate Cancer Research Centre-QLD,QUT
susan.johnson@qut.edu.au
Australia

Mrs Diana Jones
Registered Nurse
Princess Alexandra Hospital
diana_jones@health.qld.gov.au
Australia

Dr Anthony Joshua
Clinician-Scientist
Princess Margaret Hospital
anthony.joshua@doctor.com
Canada

Dr Lidija Jovanovic
Research Fellow
Princess Alexandra Hospital
lidija.jovanovic@qut.edu.au
Australia

Ms Susan Keats
Registered Nurse
St Vincents Private Hospital Sydney
skeats@stvincents.com.au
Australia

Dr Phillip Keller
Principal
West Toowoomba Medical Centre
wtwbamed@bigpond.net.au
Australia

Miss Yunee Kim
University of Toronto
yunee.kim@utoronto.ca
Canada

Miss Zaklina Kovacevic
Ph.D. Student
University of Sydney
zaklina@med.usyd.edu.au
Australia

Dr Luke Lambeth
Post Doctoral Researcher
Peter MacCallum Cancer Centre
luke.lambeth@petermac.org
Australia

Ms Rebecca Lang
Technical Assistant
Queenland Compound Library
R.Lang@griffith.edu.au
Australia

Attendee Contacts

Prof Christian Langton
Professor
Australian Prostate Cancer Research Centre - Queensland
christian.langton@qut.edu.au
Australia

Dr Jacques Lapointe
Assistant Professor
McGill University
jacques.lapointe@mcgill.ca
Canada

Dr James Lau
Medical Oncologist/Assistant Professor
CancerCare Manitoba/University of Manitoba
james.lau@cancercare.mb.ca
Canada

Dr C. Ellen Lee
Assistant Professor
University of Manitoba
celee@cc.umanitoba.ca
Canada

Dr Ting-Yim Lee
Scientist
Lawson Health Research Institute
tlee@imaging.robarts.ca
Canada

Mr Brian Lee
PhD Student
University of New South Wales/Garvan Institute of Medical Research
br.lee@garvan.org.au
Australia

Dr Margot Lehman
Staff Specialist
Princess Alexandra Hospital
Margot_Lehman@health.qld.gov.au
Australia

Dr Patrick Ling
QUT Vice Chancellor's Fellow
Australian Prostate Cancer Research Centre-Qld, QUT
mingtat.ling@qut.edu.au
Australia

Dr Felicity Lose
Research Officer
Queensland Institute of Medical Research
felicity.lose@qimr.edu.au
Australia

Dr Joanna Lubieniecka
University of British Columbia
jlubieni@interchange.ubc.ca
Canada

Miss Amy Lubik
PhD Student
Queensland University of Technology
a.lubik@qut.edu.au
Australia

Dr Rosetta Martiniello-Wilks
Head, Translational Cancer Research Group UTS
University of Technology Sydney (UTS)
Rosetta.Martiniello-Wilks@uts.edu.au
Australia

Dr Ian McKenzie
Clinical research Fellow
Australian Prostate Cancer Research Centre-Qld, QUT
ian_mckau@yahoo.com.au
Australia

Ms Inga Mertens-Walker
Postdoctoral Researcher
Australian Prostate Cancer Research Centre-Qld, QUT
imer8136@uni.sydney.edu.au
Australia

Dr Stacy Miller
Radiation Oncology Fellow
St. George Cancer Centre
s4millers@gmail.com
Australia

Prof John Mills
Director & Chair
Research Committee, National Board, Prostate Cancer Foundaiton of Australia
mills@portsea.net
Australia

Mrs Belinda Minnett
Registered Nurse
St Vincents Private Hospital
belindam@groupmomentum.com.au
Australia

Dr Benjamin Moore
Garvan Institute of Medical Research
r.pebenito@garvan.org.au
Australia

Dr Kim Moran-Jones
Research Officer
Garvan Institute of Medical Research
k.moran-jones@garvan.org.au
Australia

A/Prof Declan Murphy
Director or Urological Oncology
Peter MacCallum Cancer Centre
declan.murphy@petermac.org
Australia

Dr Leigh Murphy
Professor
University of Manitoba
lcmurph@cc.umanitoba.ca
Canada

Attendee Contacts

Dr Melanie Murrell
Research Fellow
Australian Prostate Cancer Research Centre-Qld, QUT
melanie.murrell@QUT.edu.au
Australia

Mrs Sophelia Myers
Global Editorial Director
Atlantis Healthcare
sophelia.myers@atlantishealthcare.com
Australia

Mr Russell Neal
Chief Operating Officer
Clinical Network Services (CNS) Pty Ltd
russell.neal@clinical.net.au
Australia

Prof Colleen Nelson
Executive Director & Chair, Prostate Cancer Research
Australian Prostate Cancer Research Centre-Qld, QUT
colleen.nelson@qut.edu.au
Australia

Dr Stuart Newman
Business Manager
Griffith University
s.newman@griffith.edu.au
Australia

Ms Victoria Nolan
registered nurse
Alistair Campbell Urology
practicemanager@alistaircampbellurology.com.au
Australia

Dr Christopher Ong
Research Scientist; Assisant Professor
Vancouver Prostate Centre; University of British Columbia
chris.ong@ubc.ca
Canada

Dr Marie-Odile Parat
Senior Lecturer
School of Pharmacy/UQ
m.parat@uq.edu.au
Australia

Ms Ruth Pe Benito
Garvan Institute of Medical Research
r.pebenito@garvan.org.au
Australia

Dr Helen Pearson
Post Doc
Peter MacCallum Cancer Institute
Helen.Pearson@petermac.org
Australia

Miss Lynda Perkins
Registered Nurse
blperky@westnet.com.au
Australia

Dr Morgan Pokorny
Urology Registrar
Queensland University of Technology
morganp@maxnet.co.nz
Australia

Dr Michael Pollak
Professor & Alexander Goldfarb Research Chair in Cancer Research
McGill University
michael.pollak@mcgill.ca
Canada

Dr David Pook
Medical Oncologist
Monash University
david.pook@monash.edu
Australia

Mr Christopher Poole
Queensland University of Technology
e2.oconnor@qut.edu.au
Australia

Dr Carl Power
Senior Research Associate, Senior Research Associa
University of New South Wales
c.power@unsw.edu.au
Australia

Mr Chee Jian PUA
Honours student
Australian Prostate Cancer Research Centre-Qld, QUT
chee.pua@connect.qut.edu.au
Australia

Prof Ronald Quinn
Director
Griffith University
r.quinn@griffith.edu.au
Australia

Dr Kristen Radford
Senior Research Fellow
Mater Medical Research Institute
kradford@mmri.mater.org.au
Australia

Mrs Melinda Ramsay
clinical nurse specialist
St Vincents Private Hospital Lismore
nramsay@tpg.com.au
Australia

Dr Jennifer Randall
Post-doc Translational Cancer Research Group UTS
University of Technology Sydney (UTS)
Rosetta.Martiniello-Wilks@uts.edu.au
Australia

Attendee Contacts

Prof Paul Rennie
Director, Research
Vancouver Prostate Centre
prennie@interchange.ubc.ca
Canada

Dr Anja Rockstroh
Research Fellow
Australian Prostate Cancer Research Centre-Qld, QUT
anja.rockstroh@qut.edu.au
Australia

Prof Pamela Russell
Professor, Head, Biomedical Imaging & Prostate Cancer Models
Australian Prostate Cancer Research Centre-Qld, QUT
pamela.russell@qut.edu.au
Austalia

Mr Raphael Rutkowski
PhD Student
Australian Prostate Cancer Research Centre-Qld, QUT
r.rutkowski@student.qut.edu.au
Australia

Mr Daniel Santa Mina
PhD Candidate
York University
dstamina@gmail.com
Canada

Professor Markus Seibel
The University of Sydney
markus.seibel@sydney.edu.au
Australia

A/Prof Gianluca Severi
Deputy Director
Cancer Epidemiology Centre, Cancer Council Victoria
gianluca.severi@cancervic.org.au
Australia

Miss Shirly Sieh
PhD student
Queensland University of Technology
s.sieh@qut.edu.au
Australia

Dr Ulla Simanainen
ANZAC Research Institute, University of Sydney
usimanainen@anzac.edu.au
Australia

Ms Moana Simpson
Manager
Queensland Compound Library
M.Simpson@griffith.edu.au
Australia

Professor Gurmit Singh
Professor
McMaster University
gurmit.singh@jcc.hhsc.ca
Canada

Ms Lisa Sissons
Continence Physiotherapist
lisa.sissons@yahoo.com.au
Australia

Dr David Smith
Research Fellow
Cancer Council NSW
dsmith@nswcc.org.au
Australia

Prof David Smith
Winthrop Professor
University of Western Australia
David.Smith@uwa.edu.au
Australia

Dr Carolina Soekmadji
Postdoctoral Fellow
Australian Prostate Cancer Research Centre-Qld, QUT
carolina.soekmadji@qut.edu.au
Australia

Mr Carson Stephens
Research Assistant
Queensland University of Technology
cr.stephens@qut.edu.au
Australia

Mr Grant Stuchbur
Research Fellow
Griffith University
g.stuchbury@griffith.edu.au
Australia

Dr Sarah Sutherland
Garvan Institute of Medical Research
r.pebenito@garvan.org.au
Australia

Prof Rob Sutherland
Director, Cancer Research Program
Garvan Institute of Medical Research
r.sutherland@garvan.org.au
Australia

Dr James Symons
Prostate Cancer Research Fellow
Sydney
jlpsymons@gmail.com
Australia

Dr Dennis Taaffe
The University of Queensland
dtaaffe@hms.uq.edu.au
Australia

Attendee Contacts

Mr Mark Tan
Research Assistant, Translational Cancer Research
University of Technology Sydney
Rosetta.Martiniello-Wilks@uts.edu.au
Australia

Professor Wayne Tilley
Dame Roma Mitchell Chair in Cancer Research
University of Adelaide/Hanson Institute
Wayne.Tilley@health.sa.gov.au
Australia

Ms Jan Timbrell
Registered Nurse
Lismore Base Hospital
jantimbrell@yahoo.com.au
Australia

Ms Elizabeth Tindall
CCIA / UNSW
etindall@ccia.unsw.edu.au
Australia

Dr Alan Ting
alanting@live.com
Australia

Miss Roxanne Toivanen
PhD Student
Monash University
roxanne.toivanen@med.monash.edu.au
Australia

Ms Nicole Tom
PhD student
University of Sydney
nicolet@physiol.usyd.edu.au
Australia

Dr Nham Tran
UTS Vice Chancellor's Research Fellow
University of Technology Sydney
Nham.Tran@uts.edu.au
Australia

Dr Rja Vasireddy
Postdoctoral Fellow
Australian Prostate Cancer Research Centre-Qld, QUT
raja.vasireddy@qut.edu.au
Australia

Ms. Natalie Venier
Graduate Student
University of Toronto
natalie.venier@utoronto.ca
Canada

Dr Vasundara Venkateswaran
Assistant Professor
Sunnybrook Health Sciences Centre / University of Toronto
vasundara.venkateswaran@sunnybrook.ca
Canada

Dr Hoan Vu
Research Fellow
Griffith University
hoan.vu@griffith.edu.au
Australia

Dr Amol Wagholikar
Research Scientist
CSIRO - Commonwealth Scientific and Industrial Research Organisation
amol.wagholikar@csiro.au
Australia

Mr Glen Waller
Princess Alexandra Hospital
glen_waller@health.qld.gov.au
Australia

Dr Yuzhuo Wang
Sr. Scientist/Associate Professor
Vancouver Prostate Centre/BCCA/UBC
ywang@bccrc.ca
Canada

Dr Qian Wang
Research Officer
Centenary Institute
k.wang@centenary.org.au
Australia

Prof William Watson
University College Dublin
william.watson@ucd.ie
Ireland

Ms Wendy Watts
CNC Urology Nursing
wendy.watts@hnehealth.nsw.gov.au
Australia

Mr Andrew Wheatley
awheatle@its.jnj.com
Australia

Ms Simone Wheeler
simone.wheeler@live.com
Australia

Dr William Whelan
Professor and Canada Research Chair
University of Prince Edward Island
wwhelan@upei.ca
Canada

Attendee Contacts

Mr Erik Wibowo
PhD Candidate
Dalhousie University
erik.w@dal.ca
Canada

Miss Sarah Wilkinson
PhD Student
Monash University
wilkinson830@gmail.com
Australia

Dr Scott Williams
Consultant Radiation Oncologist
Peter MacCallum Cancer Centre
scott.williams@petermac.org
Australia

Ms Louisa Windus
Research Fellow
Griffith Univeristy
l.windus@griffith.edu.au
Australia

Professor Gary Wittert
Head, Discipline of Medicine
The University of Adelaide
gary.wittert@adelaide.edu.au
Australia

Dr Edwin Wong
Research Fellow
Australian Prostate Cancer Research Centre @ Epworth
edwin.wong@epworth.org.au
Australia

Ms Sally Wormwell
Registered Nurse
St.Andrew's Continence Clinic
Toowoomba
sally.wormwell@bigpond.com
Australia

Dr Po Yee Yip
University of Sydney
poyee.yip@sswahs.nsw.gov.au
Australia

Ms Yu Yu
University of Sydney
yuyu@med.usyd.edu.au
Australia

Dr Carlo Yuen
Urologist
St Vincent's Hospital Sydney
carloyuen@hotmail.com
Australia

Dr Yuigi Yuminaga
Resident
Royal North Shore Hospital, Sydney
wyuigi@gmail.com
Australia

Ms Anousheh Zardan
University of British Columbia
azardan@prostatecentre.com
Australia

Prof Gang Zheng
Ontario Cancer Institute/University of Toronto
gang.zheng@uhnres.utoronto.ca
Canada

Australian-Canadian Prostate Cancer Research Alliance Contacts

website www.aus-canprostatealliance.org
email coordinator@aus-canprostatealliance.org